INCYTE CORP (INCY) Stock Overview
USA - NASDAQ:INCY - US45337C1027 - Common Stock
INCY Key Statistics, Chart & Performance
The current stock price of INCY is 87.31 USD. In the past month the price increased by 1.52%. In the past year, price increased by 31.51%.
INCY Latest News, Press Relases and Analysis
INCY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.42 | 400.78B | ||
| AMGN | AMGEN INC | 13.56 | 159.25B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 146.23B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.12 | 104.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.06B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.47 | 60.33B | ||
| ARGX | ARGENX SE - ADR | 90.32 | 51.24B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.14 | 34.93B | ||
| INSM | INSMED INC | N/A | 34.49B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.26B | ||
| NTRA | NATERA INC | N/A | 24.78B | ||
| BIIB | BIOGEN INC | 8.89 | 20.86B |
Related stock screener links
About INCY
Company Profile
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,617 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Company Info
INCYTE CORP
1801 Augustine Cut-Off
Wilmington DELAWARE 19803 US
CEO: Herve Hoppenot
Employees: 2617
Phone: 13024986700
INCYTE CORP / INCY FAQ
What is the stock price of INCYTE CORP today?
The current stock price of INCY is 87.31 USD. The price decreased by -0.95% in the last trading session.
What is the ticker symbol for INCYTE CORP stock?
The exchange symbol of INCYTE CORP is INCY and it is listed on the Nasdaq exchange.
On which exchange is INCY stock listed?
INCY stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INCYTE CORP stock?
33 analysts have analysed INCY and the average price target is 85.9 USD. This implies a price decrease of -1.61% is expected in the next year compared to the current price of 87.31. Check the INCYTE CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INCYTE CORP worth?
INCYTE CORP (INCY) has a market capitalization of 17.05B USD. This makes INCY a Large Cap stock.
How many employees does INCYTE CORP have?
INCYTE CORP (INCY) currently has 2617 employees.
What are the support and resistance levels for INCYTE CORP (INCY) stock?
INCYTE CORP (INCY) has a support level at 86.13 and a resistance level at 87.32. Check the full technical report for a detailed analysis of INCY support and resistance levels.
Is INCYTE CORP (INCY) expected to grow?
The Revenue of INCYTE CORP (INCY) is expected to grow by 15.11% in the next year. Check the estimates tab for more information on the INCY EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy INCYTE CORP (INCY) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of INCY, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of INCY, evaluating the profitability, health, valuation and growth aspects
- INCYTE CORP (INCY) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INCYTE CORP (INCY) Sales and EPS estimates to see what analysts future expectations are.
- INCYTE CORP (INCY) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INCYTE CORP (INCY) Insider and Institutional Ownership to learn about the owners and their transactions.
- INCYTE CORP (INCY) Stock Chart to make your own analysis
- INCYTE CORP (INCY) Latest news and press-releases to stay up to date.
Does INCYTE CORP (INCY) stock pay dividends?
INCY does not pay a dividend.
When does INCYTE CORP (INCY) report earnings?
INCYTE CORP (INCY) will report earnings on 2025-10-28, before the market open.
What is the Price/Earnings (PE) ratio of INCYTE CORP (INCY)?
The PE ratio for INCYTE CORP (INCY) is 16.69. This is based on the reported non-GAAP earnings per share of 5.23 and the current share price of 87.31 USD. Check the full fundamental report for a full analysis of the valuation metrics for INCY.
What is the Short Interest ratio of INCYTE CORP (INCY) stock?
The outstanding short interest for INCYTE CORP (INCY) is 4.56% of its float. Check the ownership tab for more information on the INCY short interest.
INCY Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to INCY. When comparing the yearly performance of all stocks, INCY is one of the better performing stocks in the market, outperforming 87.04% of all stocks.
INCY Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to INCY. INCY gets an excellent profitability rating and is at the same time showing great financial health properties.
INCY Financial Highlights
Over the last trailing twelve months INCY reported a non-GAAP Earnings per Share(EPS) of 5.23. The EPS increased by 433.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 18.99% | ||
| ROA | 14.96% | ||
| ROE | 20.88% | ||
| Debt/Equity | 0.01 |
INCY Forecast & Estimates
33 analysts have analysed INCY and the average price target is 85.9 USD. This implies a price decrease of -1.61% is expected in the next year compared to the current price of 87.31.
For the next year, analysts expect an EPS growth of 378% and a revenue growth 15.11% for INCY